DWM
DYN icon

Darwin Wealth Management’s Dyne Therapeutics DYN Stock Holding History

Darwin Wealth Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.81M Buy
154,862
+39,595
+34% +$683K 0.87% 35
2025
Q4 		$2.25M Sell
115,267
-58,250
-34% -$1.1M 0.7% 40
2025
Q3 		$2.19M Buy
173,517
+861
+0.5% +$9.82K 0.7% 40
2025
Q2 		$1.64M Buy
172,656
+120,566
+231% +$1.33M 0.57% 51
2025
Q1 		$1.23M Hold
52,090
– – 0.41% 63
2024
Q4 		$1.23M Buy
+52,090
New +$1.54M 0.41% 63

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Darwin Wealth Management's DYN Position: Q1 2026 in Review

Darwin Wealth Management increased its Dyne Therapeutics (DYN) stake by 34% in Q1 2026, buying an estimated $683K and bringing the position to 154,862 shares worth $2.81M. The position accounts for 0.87% of the portfolio, ranked #35.

Darwin Wealth Management first reported a position in DYN in Q4 2024 and has held it in 6 quarters since. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Darwin Wealth Management held 154,862 shares of Dyne Therapeutics worth $2.81M as of Q1 2026.
  • Darwin Wealth Management bought 39,595 Dyne Therapeutics shares in Q1 2026, an estimated $683K.
  • Dyne Therapeutics made up 0.87% of Darwin Wealth Management's portfolio in Q1 2026, its #35 holding.
  • Darwin Wealth Management first reported a position in Dyne Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Darwin Wealth Management's 13F filing for Q1 2026, filed 1 May 2026.